Users' guides to the medical literature XVI. How to use a treatment recommendation

JAMA

Volumn 281, Issue 19, 1999, Pages 1836-1843

  Guyatt, Gordon H ^a,c   Sinclair, Jack ^a   Cook, Deborah J ^a   Glasziou, Paul ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ANTICOAGULATION; BLEEDING; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT PLANNING;

EID: 0033583746     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.19.1836     Document Type: Review

References (29)

1. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
2. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
3. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:5795-5895.
4. Glasziou PP, Irwig LM. An evidence-based approach to individualising treatment. BMJ. 1995;311: 1356-1358.
5. Smith GD, Egger N. Who benefits from medical interventions? BMJ. 1993;308:72-74.
6. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA. 1992;268:240-248.
7. Oxman AD, Cook DJ, Guyatt GH, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VI: how to use an overview. JAMA. 1994;272:1367-1371.
8. Oxman AD, Guyatt GH, A consumer's guide to subgroup analysis. Ann Intern Med. 1992;116:78-84.
9. Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VII: how to use a clinical decision analysis, A: are the results of trie study valid? JAMA. 1995;273:1292-1295.
10. Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VII: how to use a clinical decision analysis, B: what are the results and will they help me in caring for my patients? JAMA. 1995;273:1610-1613.
11. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland DK, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature. XIII: how to use an article on economic analysis of clinical practice, A: are the results of the study valid? JAMA. 1997;277:1552-1557.
12. O'Brien BJ, Heyland DK, Richardson WS, Levine M, Drummond MF, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, XIII: how to use an article on economic analysis of clinical practice, B: what are the results and will they help me in caring for my patients? JAMA. 1997: 277:1802-1806.
13. Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt GH, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VIII: how to use clinical practice guidelines, A: are the recommendations valid? JAMA. 1995;274:570-574.
14. Wilson MC, Hayward RS, Tunis SR, Bass EB, Guyatt GH, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VIII: how to use clinical practice guidelines, B: what are the recommendations and will they help you in caring for your patients? JAMA. 1995;274:1630-1632.
15. Vandenbroucke-Grauls CMJ, Vendenbroucke JP. Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet. 1991;338:859-862.
16. Selective Decontamination of the Digestive Tract Trialists' Collaborative Group. Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. BMJ. 1993;307: 525-532.
17. Heyland DK, Cook DJ, Jaeschke R, Griffith L, Lee HN, Guyatt GH. Selective decontamination of the digestive tract. Chest. 1994;105:1221-1229.
18. Kollef MH. The rote of selective digestive tract decontamination on mortality and respiratory tract infections. Chest. 1994;105:1101-1108.
19. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
20. Guyatt GH, Sackett DL, Sinclair JC, Hayward RS, Cook DJ, Cook RJ, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, IX: a method for grading health care recommendations. JAMA. 1995;274:1800-1804.
21. Caro JJ, Groome PA, Flegel KM. Atrial fibrillation and anticoagulation: from randomised trials to practice. Lancet. 1993;341:1381-1384.
22. Grootendoorst P, Feeny D, Furlong W. Health utilities index mark 3: evidence of construct validity for stroke and arthritis in a population health survey. Med Care. In press.
23. Glasziou P, Bromwich LS, Simes RJ. Quality of life six months after myocardial infarction treated with thrombolytic therapy. Med J Aust. 1994;161:532-536.
24. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preference for stroke outcomes. Stroke. 1994;25:1721-1725.
25. Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
26. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-1457.
27. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ. 1992; 146:473-481.
28. Silvestri G, Pritchard R, Welch G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998;317:771-775.
29. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366.